Table 1.
Patient characteristics.
| No. of patients | 18 |
|
| |
| Median age (range) | 57.5 (35–69) |
| >60 | 8 |
| <60 | 10 |
|
| |
| Sex (M : F) | 16 : 2 |
|
| |
| Stage of myeloma disease according Durie & Salmon | |
| IIIA | 17 |
| IIIB | 1 |
|
| |
| Type of myeloma: | |
| IgG | 12 |
| IgA | 2 |
| Light Chain | 4 |
|
| |
| Transplant | |
| Upfront therapy | 16 |
| After achieving remission in a relapsed disease | 2 |
|
| |
| Chemotherapy regimen prior Tx | |
| VAD | 3 |
| Dexamethasone and Thalidomide | 9 |
| Velcade | 4 |
| Lenalidomide | 2 |
|
| |
| Time followed up since diagnosis (Months) | 47.5 (35–81) |
|
| |
| Time followed up since First transplant (Months) | 35 (29–49) |
|
| |
| High risk disease; stage III with hypercalcaemia, renal failure, high B2 Microglobulin | 8 |
| High cytogenetic risk (e.g. 13q-, 17p-, t(4,14)) | 6 |
| Patients with stage III disease with standard risk factors | 4 |
|
| |
| Outcome of the disease | |
| Alive | 16 |
| Complete remission | 4 |
| Partial remission | 12 |
| Deceased due to disease progression | 2 |